RA
ENTA icon

Royce & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Royce & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,340
Closed -$235K – 993
2021
Q2 		$235K Sell
5,340
-592
-10% -$29K ﹤0.01% 980
2021
Q1 		$293K Sell
5,932
-4,748
-44% -$237K ﹤0.01% 984
2020
Q4 		$450K Buy
10,680
+170
+2% +$7.48K ﹤0.01% 903
2020
Q3 		$481K Buy
10,510
+32
+0.3% +$1.55K 0.01% 867
2020
Q2 		$526K Buy
10,478
+136
+1% +$7.04K 0.01% 853
2020
Q1 		$532K Buy
10,342
+3,062
+42% +$163K 0.01% 821
2019
Q4 		$450K Buy
7,280
+3,597
+98% +$223K ﹤0.01% 902
2019
Q3 		$221K Buy
3,683
+3,403
+1,215% +$253K ﹤0.01% 974
2019
Q2 		$24K Buy
280
+5
+2% +$450 ﹤0.01% 1102
2019
Q1 		$26K Sell
275
-13
-5% -$1.17K ﹤0.01% 1104
2018
Q4 		$20K Buy
288
+25
+10% +$1.92K ﹤0.01% 1106
2018
Q3 		$22K Buy
263
+141
+116% +$14.1K ﹤0.01% 1147
2018
Q2 		$14K Buy
122
+17
+16% +$1.7K ﹤0.01% 1181
2018
Q1 		$8K Sell
105
-83
-44% -$6.39K ﹤0.01% 1207
2017
Q4 		$11K Buy
+188
New +$9.41K ﹤0.01% 1166

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Royce & Associates's ENTA Position: Q3 2021 in Review

Royce & Associates sold out of Enanta Pharmaceuticals (ENTA) in Q3 2021, closing a stake of 5,340 shares — an estimated $235K sold.

Royce & Associates first reported a position in ENTA in Q4 2017 and held it in 15 quarters. The position peaked at $532K in Q1 2020. 148 funds tracked by Wall St. Rank hold ENTA as of Q3 2021.

  • Royce & Associates reported no remaining Enanta Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Royce & Associates sold 5,340 Enanta Pharmaceuticals shares in Q3 2021, an estimated $235K.
  • Royce & Associates first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Royce & Associates's Enanta Pharmaceuticals position peaked at $532K in Q1 2020.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2021.

Based on Royce & Associates's 13F filing for Q3 2021, filed 10 Nov 2021.